SITC 2023 | Glycosylated proteins are predictive of immunotherapy response in metastatic melanoma

Yana Najjar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, provides an overview of the key findings from her research into glycosylated protein biomarkers as predictors for immunotherapy response in metastatic melanoma. There is an unmet need for clinically predicting immunotherapy responses in patients; other -omics techniques have identified biomarkers but there is an inability to process and reproduce such huge amounts of data. Dr Najjar tackles this by using an LCMS AI algorithm to predict, with high fidelity, patients’ responses to immunotherapies in different cohorts using glycoproteomic biomarkers. The study has also identified fucosylation is indicative of poorer overall survival, with the next steps being to validate these promising findings. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.